Linzagolix not checked
Kissei Pharmaceutical Co., Ltd. · OBE2109 · KLH-2109
FollowEvery change as it happens, and a Monday email
Trials
2 active
11 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “\- KLH-2109 tablet: Oral administration \- Leuprorelin acetate placebo: Subcutaneous administration”In the company’s words, NCT07015268 on ClinicalTrials.gov
- Tested for
- Endometriosis
- Main trialPhase 3
- “To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.”In the company’s words, NCT07015268 on ClinicalTrials.gov
- Other names
- OBE2109 · KLH-2109
Other drugs for Endometriosis
- ElagolixAbbVie · Phase 3
- HMI-115Hope Medicine (Nanjing) Co., Ltd · Phase 3
- RelugolixSumitomo Pharma America, Inc. · Phase 3
- VipoglanstatGesynta Pharma AB · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
- HHK001Huahai Pharmaceutical (Huaota) · Phase 1
Coming up1
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2027 | A Clinical Study of KLH-2109 in Patients With Endometriosis | |
| Phase 3Completed | 16 Sep 2019 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids | |
| Phase 3Completed | 14 Apr 2020 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids | |
| Phase 3Terminated | 6 Jan 2021 | A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain | |
| Phase 3Terminated | 8 Jan 2021 | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain | |
| Phase 3Completed | 18 Oct 2021 | Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. | |
| Phase 3Completed | 15 Sep 2022 | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) | |
| Phase 3Completed | 16 Feb 2024 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | |
| Phase 3Completed | 21 Aug 2024 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | |
| Phase 2Completed | Apr 2018 | A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis | |
| Phase 2Authorised | not given | Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026